Reneo Pharmaceuticals Q3 2023 Earnings Report
Key Takeaways
Reneo Pharmaceuticals reported a net loss of $19.2 million, or $0.57 per share, for the third quarter of 2023. The company had $125.6 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Topline data results from the pivotal STRIDE study are expected in December 2023.
Completed last patient last visit in the pivotal STRIDE study; topline results expected in December 2023
Enrolled 88% of eligible STRIDE study patients in the STRIDE AHEAD open-label extension study; 65 patients treated beyond 52-weeks
Dosed the first patient with PMM due to a nuclear DNA (nDNA) defect in the STRIDE AHEAD open-label extension study
Repurchased 576,443 shares of common stock for approximately $4.4 million on October 30, 2023; all repurchased shares were retired
Reneo Pharmaceuticals
Reneo Pharmaceuticals
Forward Guidance
The company anticipates sharing topline results of the pivotal STRIDE study in December.